News and market insights

Why so many Aussie Biotechs Fail

Why so many Aussie Biotechs Fail

Our managing Director, Dr Charlie Williams PhD, was interviewed by Jared Lynch from The Australian this month, talking about the differences between the Australian and US Biotechnology sectors

read more
Sticking to your Guns

Sticking to your Guns

Looking back at FY23, one of the things that most stands out is that the level of outperformance achieved has reinforced the importance of Sticking to your Guns: Adherence to investment protocols.

read more
MnA Gathers Pace

MnA Gathers Pace

With global biotechnology on the recovery path since its recent correction, the rising pace of M&A within the industry is playing a key role in the recovery – a dynamic we expect to continue.

read more
Letter from America

Letter from America

While all major US indices ended CY 2022 in the red, HB Biotechnology fared much better, delivering a 6.8% return for the calendar year.

read more